CN105934243A - 治疗肝病症的方法 - Google Patents

治疗肝病症的方法 Download PDF

Info

Publication number
CN105934243A
CN105934243A CN201580004269.XA CN201580004269A CN105934243A CN 105934243 A CN105934243 A CN 105934243A CN 201580004269 A CN201580004269 A CN 201580004269A CN 105934243 A CN105934243 A CN 105934243A
Authority
CN
China
Prior art keywords
compound
formula
administered
group
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580004269.XA
Other languages
English (en)
Chinese (zh)
Inventor
松田和子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN105934243A publication Critical patent/CN105934243A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201580004269.XA 2014-01-10 2015-01-07 治疗肝病症的方法 Pending CN105934243A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/152,924 US8962687B2 (en) 2012-12-05 2014-01-10 Method of treating liver disorders
US14/152,924 2014-01-10
PCT/US2015/010479 WO2015105874A1 (en) 2014-01-10 2015-01-07 Method of treating liver disorders

Publications (1)

Publication Number Publication Date
CN105934243A true CN105934243A (zh) 2016-09-07

Family

ID=50826043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580004269.XA Pending CN105934243A (zh) 2014-01-10 2015-01-07 治疗肝病症的方法

Country Status (10)

Country Link
US (2) US8962687B2 (enExample)
EP (1) EP3091972B1 (enExample)
JP (2) JP2017502056A (enExample)
KR (1) KR102352729B1 (enExample)
CN (1) CN105934243A (enExample)
BR (1) BR112016015712A8 (enExample)
CA (1) CA2935933C (enExample)
ES (1) ES2917982T3 (enExample)
TW (1) TW201609081A (enExample)
WO (1) WO2015105874A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950909C (en) * 2014-06-02 2023-03-28 Medicinova, Inc. Method of inhibiting or treating fibrosis
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CN110099690B (zh) * 2017-11-30 2021-10-26 北京通复堂生物科技股份有限公司 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
JP2024522030A (ja) * 2021-05-28 2024-06-10 メディシノバ・インコーポレイテッド フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158123A1 (en) * 2011-12-08 2013-06-20 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
FI76778C (fi) 1986-09-22 1988-12-12 Kyro Oy Foerfarande och anordning foer transport av glasskivor under upphettning och haerdning.
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158123A1 (en) * 2011-12-08 2013-06-20 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
徐珊等: "肝纤维化不同证型与肝功能和肝组织羟脯氨酸关系的实验研究", 《中华中医药学刊》 *

Also Published As

Publication number Publication date
EP3091972B1 (en) 2022-06-01
CA2935933A1 (en) 2015-07-16
JP2019218379A (ja) 2019-12-26
KR102352729B1 (ko) 2022-01-18
JP2017502056A (ja) 2017-01-19
US20150209314A1 (en) 2015-07-30
CA2935933C (en) 2022-06-28
WO2015105874A1 (en) 2015-07-16
ES2917982T3 (es) 2022-07-12
EP3091972A4 (en) 2017-08-23
US8962687B2 (en) 2015-02-24
BR112016015712A2 (pt) 2017-08-08
KR20160099716A (ko) 2016-08-22
EP3091972A1 (en) 2016-11-16
TW201609081A (zh) 2016-03-16
BR112016015712A8 (pt) 2018-04-17
US20140155484A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
JP2019218379A (ja) 肝障害の治療方法
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
JP6672173B2 (ja) 進行した非アルコール性脂肪性肝炎の治療方法
CN106232108B (zh) 治疗特发性肺纤维化的制药用途
JP6469727B2 (ja) 線維症の抑制又は治療方法
US12239620B2 (en) Methods to decrease triglyceride synthesis in the liver
CN112930211A (zh) 包含15-HEPE和/或15-HETrE的组合物以及治疗或预防心血管代谢疾病、代谢综合征和/或相关疾病的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160907